We propose a Bayesian adaptive two-stage design for the efficient estimation of the maximum dose or the minimum effective dose in a dose-finding trial. The new design allocates subjects in stage two according to the posterior distribution of the target dose location. Simulations show that the proposed two-stage design is superior to equal allocation and to a two-stage strategy where only one dose is left in the second stage
This dissertation explores phase I dose-finding designs in cancer trials from three perspectives: th...
This dissertation explores phase I dose-finding designs in cancer trials from three perspectives: th...
A phase I dose-finding clinical trial has always been a challenge to find a safe dosage, given a ver...
We propose a Bayesian adaptive two-stage design for the efficient estimation of the maximum dose or ...
Background: For most cytotoxic and biologic anti-cancer agents, the response rate of the drug is com...
We propose a robust two-stage design to identify the optimal biological dose for phase I/II clinical...
The primary objective of phase I dose-finding trials is to determine the maximum tolerated dose (MTD...
My dissertation focuses mainly on Bayesian adaptive designs for phase I and phase II clinical trials...
Adaptive trial designs can considerably improve upon traditional designs, by modifying design aspect...
The landscape of drug development in oncology has changed from conventional chemotherapies to molecu...
Integrated phase I-II clinical trial designs are efficient approaches to accelerate drug development...
We consider a dose-finding trial in phase IIB of drug development. For choosing an appropriate desi...
My dissertation work primarily focuses on Bayesian adaptive design for phase I and phase II clinical...
This dissertation explores phase I dose-finding designs in cancer trials from three perspectives: th...
This dissertation explores phase I dose-finding designs in cancer trials from three perspectives: th...
This dissertation explores phase I dose-finding designs in cancer trials from three perspectives: th...
This dissertation explores phase I dose-finding designs in cancer trials from three perspectives: th...
A phase I dose-finding clinical trial has always been a challenge to find a safe dosage, given a ver...
We propose a Bayesian adaptive two-stage design for the efficient estimation of the maximum dose or ...
Background: For most cytotoxic and biologic anti-cancer agents, the response rate of the drug is com...
We propose a robust two-stage design to identify the optimal biological dose for phase I/II clinical...
The primary objective of phase I dose-finding trials is to determine the maximum tolerated dose (MTD...
My dissertation focuses mainly on Bayesian adaptive designs for phase I and phase II clinical trials...
Adaptive trial designs can considerably improve upon traditional designs, by modifying design aspect...
The landscape of drug development in oncology has changed from conventional chemotherapies to molecu...
Integrated phase I-II clinical trial designs are efficient approaches to accelerate drug development...
We consider a dose-finding trial in phase IIB of drug development. For choosing an appropriate desi...
My dissertation work primarily focuses on Bayesian adaptive design for phase I and phase II clinical...
This dissertation explores phase I dose-finding designs in cancer trials from three perspectives: th...
This dissertation explores phase I dose-finding designs in cancer trials from three perspectives: th...
This dissertation explores phase I dose-finding designs in cancer trials from three perspectives: th...
This dissertation explores phase I dose-finding designs in cancer trials from three perspectives: th...
A phase I dose-finding clinical trial has always been a challenge to find a safe dosage, given a ver...